Illinois is currently home to 2627 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858
Recruiting
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized myasthenia gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Northwestern University - Parkinson's Disease and Movement Disorders Center, Chicago, Illinois
Conditions: Generalized Myasthenia Gravis
Register for Updates
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
NCT04978727
Recruiting
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and destroy them. The survivin protein can be found on up to 95% of glioblastomas and other types of cancer but is not found in normal cells. If the body's immune system knows to destroy cells that express surviv... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/11/2025
Locations: Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
04/11/2025
Locations: Research Site #108, Chicago, Illinois
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
NCT04664634
Recruiting
The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
04/11/2025
Locations: Northwestern University, Evanston, Illinois
Conditions: Dysphagia, Parkinson Disease
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Metastatic Urothelial Cancer
Register for Updates
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542
Recruiting
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2025
Locations: Research Site 2, Chicago, Illinois
Conditions: SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Register for Updates
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 Diabetes
NCT06865989
Recruiting
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 diabetes. Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting. Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Period 1) the... Read More
Gender:
ALL
Ages:
Between 2 years and 70 years
Trial Updated:
04/10/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 1
Register for Updates
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
NCT06837246
Recruiting
This is a double-blind, randomized, 12-week parallel study that aims to determine the effects of a cognitive nutritional supplement for 12 weeks on cognition parameters specific to attention/focus related domains, compared to a placebo control, in a general population of adult men and women in the United States.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
04/10/2025
Locations: Biofortis Innovation Services, Addison, Illinois
Conditions: Cognition, Concentration, Attention, Focus
Register for Updates
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962
Recruiting
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Crohns Disease
Register for Updates
Circadian Mechanisms, Glucose, and CV Risks in T1D
NCT06624046
Recruiting
People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population. Improving sleep regularity has been associated with improved glycemic markers however mechanisms by which improving sleep regularity improves metabolic and cardiovascular health is not known. The investigators propose to conduct a mechanistic study using a sleep stability manipulation. This proposal will advance t... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/10/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Type 1 Diabetes (T1D)
Register for Updates
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974
Recruiting
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Gender:
ALL
Ages:
Between 18 years and 83 years
Trial Updated:
04/10/2025
Locations: Chicago, Chicago, Illinois
Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Register for Updates
A Study to Investigate Safety and Effectiveness of Pocine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
NCT06575426
Recruiting
This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.
Gender:
ALL
Ages:
Between 35 years and 65 years
Trial Updated:
04/10/2025
Locations: University of Illinois Hospital &Health Scences System, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation
Register for Updates